Microbix Announces Extension of Warrant Expiry Date
By Pavel Zhelev | May 19, 2023Microbix Presenting at the 2023 Bloom Burton Conference
By Pavel Zhelev | April 20, 2023
Microbix Announces Annual and Special Meeting Voting Results
By Pavel Zhelev | March 30, 2023
Governments of Ontario and Canada Invest in Microbix
By Pavel Zhelev | March 20, 2023
Microbix Supporting Australian Point-of-Care Testing Program
By Pavel Zhelev | March 1, 2023
Microbix Reports Results for Q1 Fiscal 2023
By Pavel Zhelev | February 9, 2023
Microbix Presenting Results of Collaboration with Health PEI
By Pavel Zhelev | February 6, 2023
Microbix Launches QAP to Support “Monkeypox” Testing
By Pavel Zhelev | January 30, 2023
Microbix Reports Record Sales for Fiscal 2022
By Pavel Zhelev | December 22, 2022
Microbix Presenting Test-Workflow Validation Results at EMMD
By Pavel Zhelev | October 6, 2022
Microbix Announces Initiation of Normal Course Issuer Bid
By Pavel Zhelev | September 28, 2022
Microbix Presenting at Muskoka Capital Conference
By Pavel Zhelev | September 21, 2022
Microbix Reports Results for Q3 Fiscal 2022
By Pavel Zhelev | August 12, 2022
Microbix Executes Substantial QAPs Supply Agreement
By Pavel Zhelev | August 10, 2022Microbix Presenting STI Multiplex Test Controls at AACC
By Pavel Zhelev | July 26, 2022
Microbix Presenting Test Validation Methods at AACC
By Pavel Zhelev | June 3, 2022
Microbix Reports Record Results for Q2 Fiscal 2022
By Pavel Zhelev | May 12, 2022
Microbix Presenting Omicron Test Control Results at CVS
By Pavel Zhelev | April 29, 2022
Microbix Presenting at the 2022 Bloom Burton Conference
By Pavel Zhelev | April 28, 2022
Microbix Presenting Respiratory Virus Controls Data at Two Events
By Pavel Zhelev | April 19, 2022
Microbix Presenting HPV Product Results at EUROGIN
By Pavel Zhelev | April 8, 2022
Microbix Announces Annual and Special Meeting Voting Results
By Pavel Zhelev | March 31, 2022
Microbix Invests to Further Scale Its Business
By Pavel Zhelev | March 29, 2022
Virtual AGM on March 30, 2022
By Pavel Zhelev | March 8, 2022
Microbix Announces Issuance of Stock Options
By Pavel Zhelev | February 24, 2022
Microbix Announces Nomination to Board of Directors
By Pavel Zhelev | February 22, 2022
Microbix Presenting at Capital Conference in B.C.
By Pavel Zhelev | February 17, 2022
Microbix Advances Commissioning of Sites Two and Three
By Pavel Zhelev | February 15, 2022
Microbix Reports Record Results for Q1 Fiscal 2022
By Pavel Zhelev | February 10, 2022
Microbix Launches Omicron Variant Test Control
By Pavel Zhelev | February 1, 2022
Microbix Receives $4.7 Million Order for Viral Transport Medium
By Pavel Zhelev | December 24, 2021
Microbix Reports Record Results for Fiscal 2021
By Pavel Zhelev | December 23, 2021
Microbix Launches Multiplex Respiratory PCR-Test Control
By Pavel Zhelev | December 20, 2021
Microbix Expands Pandemic Test Controls (QAPs™) Portfolio
By Pavel Zhelev | November 17, 2021
Microbix Receives $2.7 Million from Exercise of Warrants
By Pavel Zhelev | October 27, 2021
Microbix Poster Covering SARS-CoV-2 Variants of Concern (VOC) QAPs at AACC 2021
By Pavel Zhelev | October 6, 2021
Microbix Makes Early Repayment of 9% Interest Debenture
By Pavel Zhelev | October 4, 2021
Microbix Presenting Product Results at AACC
By Pavel Zhelev | September 27, 2021
Microbix Presenting at Muskoka Capital Conference
By Pavel Zhelev | September 23, 2021
Microbix Reports Record Results for Q3 Fiscal 2021
By Pavel Zhelev | August 12, 2021
Microbix Upgrades U.S. OTC Market & Investor Relations
By Pavel Zhelev | August 3, 2021
Microbix Posters at 31st ECCMID 2021
By Pavel Zhelev | July 16, 2021
Microbix Presenting Product Results to Industry
By Pavel Zhelev | July 8, 2021
Microbix Announces Quality Products Distribution Agreement
By Pavel Zhelev | July 7, 2021
Microbix Secures Third Ontario Manufacturing Site
By Pavel Zhelev | June 3, 2021
Microbix Announces Quality Products Distribution Agreement
By Pavel Zhelev | May 31, 2021
Microbix Announces Closing of Offering and Private Placement
By Pavel Zhelev | May 19, 2021
Microbix Reports Record Results for Q2 Fiscal 2021
By Pavel Zhelev | May 13, 2021
Microbix Announces $6.0 Million of Financings
By Pavel Zhelev | April 28, 2021
Microbix & SpeeDx Form Exclusive Collaboration
By Pavel Zhelev | April 26, 2021
Microbix Receives $4.25 Million Order For Viral Transport Medium
By Pavel Zhelev | April 23, 2021
Microbix to Present at Bloom Burton Investor Conference
By Pavel Zhelev | April 19, 2021
Microbix Announces Annual and Special Meeting Voting Results
By Pavel Zhelev | March 31, 2021
Virtual AGM on March 30, 2021
By Pavel Zhelev | March 30, 2021
Microbix & Seegene Canada Form COVID-Variant Collaboration
By Pavel Zhelev | March 15, 2021
Microbix Antigen-test QAPs Now Available For Clinical Use
By Pavel Zhelev | March 11, 2021
Microbix Announces Issuance of Stock Options
By Pavel Zhelev | February 18, 2021
Microbix Announces Quality Products Distribution Agreement
By Pavel Zhelev | February 16, 2021
Microbix Reports Results for Q1 Fiscal 2021
By Pavel Zhelev | February 11, 2021
Microbix Announces Material First Sales of Viral Transport Medium
By Pavel Zhelev | February 9, 2021
Microbix Viral Transport Medium Now Available
By Pavel Zhelev | January 28, 2021
Microbix & Copan Italia Execute Strategic Agreement
By Pavel Zhelev | December 21, 2020
Microbix Reports Results for Fiscal 2020
By Pavel Zhelev | December 18, 2020
Microbix Presenting Product Results at AACC
By Pavel Zhelev | December 15, 2020
Microbix Announces Addition to Board of Directors
By Pavel Zhelev | December 7, 2020